Merck & Company Inc (MRK)vsPrivia Health Group Inc (PRVA)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PRVA
Privia Health Group Inc
$20.42
+0.25%
HEALTHCARE · Cap: $2.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2723% more annual revenue ($66.57B vs $2.36B). MRK leads profitability with a 4.8% profit margin vs 1.2%. PRVA trades at a lower P/E of 92.8x. PRVA earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold36
out of 100
Grade: F
PRVA
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for PRVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Earnings expanding 250.0% YoY
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
ROE of 0.0% — below average capital efficiency
1.2% margin — thin
Operating margin of 1.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 92.8x leaves little room for execution misses. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.88 — expect wider price swings.
PRVA is growing revenue faster at 21.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PRVA scores higher overall (50/100 vs 36/100) and 21.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?